The mission of the Clinical Trials Support Resource is to serve the patients, faculty, and staff of the University of Texas M.D. Anderson Cancer Center by facilitating the approval and performance of clinical research of the highest quality in an ethical and cost-effective fashion. The Clinical Trials Support Resource is supported by the Office of Protocol Research (OPR) staff and is directed by the Associate Vice President for Clinical and Translational Research and an Administrative Director and is divided into four specialized areas: Protocol Approval and Regulatory Affairs, Office of Clinical Research Quality Assurance, Protocol Data Management System, and Research Finance. The Protocol Approval and Regulatory Affairs area supports the protocol approval process for the clinical Research Committee; the Psychosocial, Behavioral, and Health Services Research Committee; and the Surveillance Committee (Institutional Review Board) to ensure that scientific and patient protection issues are adequately addressed and that the protocols are approved at the institutional level before they are submitted to the NCI for approval. The Office of Clinical Research Quality Assurance monitors the quality of research data, serves as resource in improving data management, and provides an institutional mechanism for managing issues related to research deficiencies or problems. This office works closely with the Protocol Approval and Regulatory Affairs staff to ensure that the NCI stipulations are being met and that the requirement for the PRMS designation in protocol accrual is monitored is fulfilled. The Protocol Data Management System staff supports a comprehensive database developed for clinical research personnel at M.D. Anderson Cancer Center. It provides on-line patient registration for all clinical research protocols and is primarily responsible for tracking submission, patient accrual, adverse events, annual reviews, activations, and terminations for all clinical research protocols. It too plays a critical role in the PMRS process. The Research Finance staff is responsible for overseeing the protocol activity in the Clinical Research Unit and utilizing a cost model to prospectively project the cost and charge of protocols. Although each area is involved with special projects, the primary focus of the Clinical Trials Support Resource is to ensure that the principal investigators are in compliance with federal and institutional regulations, to maintain protocol-related information for the institution, to provide protocol management services to investigators, and to refine the financial system surrounding clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-25S1
Application #
6347269
Study Section
Project Start
2000-08-30
Project End
2001-06-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2000
Total Cost
$254,104
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Tayob, Nabihah; Richardson, Peter; White, Donna L et al. (2018) Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol 18:1
Caruso, Joseph A; Duong, Mylinh T; Carey, Jason P W et al. (2018) Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res 78:5481-5491
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477

Showing the most recent 10 out of 12418 publications